Sign inJoin waitlistJoin the waitlist

Maximilian Diehn

Vice Chair of Research · Stanford Health Care

Credentials: · · · ·

History

Research · Stanford Health Care
Present
Radiation & Cancer Biology Division · Stanford Health Care
Present
Radiation and Cancer Biology & Vice Chair of Research Division · Stanford Health Care
Present

Stanford University Dept of Radiation Oncology (2009) CA
2005–2009
Stanford University, Biophysics
2004–2005
Stanford University, Biophysics
Stanford University School of Medicine
2000–2004
MD, Stanford University
1989–1993

Research

Robust enumeration of cell subsets from tissue expression profiles
Nature Methods · 2015 · 10,621 citations
Determining cell type abundance and expression from bulk tissues with digital cytometry
Nature Biotechnology · 2019 · 3,521 citations
The prognostic landscape of genes and infiltrating immune cells across human cancers
Nature Medicine · 2015 · 2,564 citations

Billy Loo
93 papers
Ash Alizadeh
75 papers · 4 as a resident
Heather Wakelee
46 papers
Joel Neal
39 papers
David Kurtz
30 papers
Michael Gensheimer
26 papers · 3 as a resident
Aadel Chaudhuri
22 papers · 12 as a resident
Michael Binkley
22 papers · 14 as a resident
Alexander Chin
18 papers · 1 as a resident
Lucas Vitzthum
17 papers
Sukhmani Padda
17 papers
DS
David Shultz
16 papers · 8 as a resident

Grants

Integrating Genomic & Epigenomic Features for Noninvasive Characterization of T-Cell Lymphomas
National Cancer Institute · R01
PI · $639K · Stanford University
2026–2031
Noninvasive Imaging and Blood Biomarkers for Personalized Lung Cancer Immunotherapy
National Cancer Institute · R01
PI · $1.9M · Stanford University
2024–2029
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy
National Cancer Institute · P01
PI · $10M · Stanford University
2022–2027
Analysis of Urine Tumor Nucleic Acids for Detection and Personalized Surveillance of Bladder Cancer
National Cancer Institute · R01
Contact PI · $3M · Stanford University
2020–2026

Clinical trials

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Principal investigator · Recruiting · Phase 3
Maximilian Diehn
2021–2028
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
Maximilian Diehn
2016–2023
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Principal investigator · Completed · Phase 1
Stanford University
2016–2020
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Principal investigator · Completed
Stanford University
2011–2022